A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
Study sponsor: Palvella Therapeutics, Inc. · PVLA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-08Estimated
Enrollment · participants15Estimated
Source updated2026-04-27Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.